Creative Planning raised its stake in shares of Syneos Health, Inc. (NASDAQ:SYNH – Free Report) by 45.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,164 shares of the company’s stock after purchasing an additional 2,844 shares during the period. Creative Planning’s holdings in Syneos Health were worth $386,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. OLD Mission Capital LLC purchased a new stake in shares of Syneos Health during the 4th quarter valued at about $31,000. Harbor Capital Advisors Inc. purchased a new stake in shares of Syneos Health during the 2nd quarter valued at about $36,000. Mesirow Institutional Investment Management Inc. purchased a new stake in shares of Syneos Health during the 1st quarter valued at about $38,000. Nomura Asset Management Co. Ltd. raised its position in shares of Syneos Health by 115.1% during the 1st quarter. Nomura Asset Management Co. Ltd. now owns 1,140 shares of the company’s stock valued at $41,000 after buying an additional 610 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Syneos Health by 33.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 1,399 shares of the company’s stock valued at $50,000 after buying an additional 354 shares in the last quarter. Institutional investors own 91.16% of the company’s stock.
Analyst Ratings Changes
Separately, StockNews.com began coverage on shares of Syneos Health in a research report on Tuesday. They issued a “hold” rating on the stock. Seven investment analysts have rated the stock with a hold rating, According to MarketBeat.com, Syneos Health presently has a consensus rating of “Hold” and an average target price of $40.00.
Syneos Health Stock Performance
Shares of NASDAQ:SYNH opened at $42.98 on Friday. The firm has a market cap of $4.46 billion, a PE ratio of 62.29 and a beta of 1.58. The firm’s 50 day simple moving average is $42.79 and its 200-day simple moving average is $41.67. Syneos Health, Inc. has a one year low of $22.89 and a one year high of $52.23. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.20 and a current ratio of 1.20.
Syneos Health (NASDAQ:SYNH – Get Free Report) last issued its earnings results on Tuesday, August 8th. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.63). The company had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.26 billion. Syneos Health had a return on equity of 8.63% and a net margin of 1.31%. As a group, equities analysts predict that Syneos Health, Inc. will post 2.79 EPS for the current year.
Syneos Health Company Profile
Syneos Health, Inc, operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development.
Featured Articles
- Five stocks we like better than Syneos Health
- How to Invest in Apparel Stocks
- Institutions Buy Consumer Staples, is the Bottom in?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Fastenal or Simpson Manufacturing: Which is the Better Buy?
- How to Invest in Communication Stocks
- Can These 3 Semiconductor Stocks Outpace Nvidia’s Growth?
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.
